Pipeline Drug Substance 1
| Number | Stracture | Product | Status | Indication | Manufacturing Process | |
|---|---|---|---|---|---|---|
| 1 |
|
Exatecan | Lab | HER-2 Breast Cancer | Total Synthesis |
|
| 2 |
|
SM-02 | Pilot | Key Intermidiate for SN-38 and Exatecan | Total Synthesis |
|
| 3 |
|
Polysulfated Glycosaminoglycan | Lab | Anti-tumor | Semi-synthetic |
|
| 4 |
|
Berberine HCI | Pilot | Anti-infective | Total Synthesis |
|
| 5 |
|
Conjugated Estrogens | Lab | Estrogen Supplements | Total Synthesis |
|
Pipeline Drug Substance 2
| Number | Stracture | Product | Target | Indication | First Launched Time/Country | Patent | |
|---|---|---|---|---|---|---|---|
| 1 |
|
Fezolinetant ☆ | NK-3R | VMS | 2023-05, US | 2034-03 |
|
| 2 |
|
Resmetirom | THR-β | NASH/MASH | 2024-03, US | 2026-06 |
|
| 3 |
|
Etrasimod | S1PR | Ulcerative Colitis | 2023-10, US | 2030-03 |
|
| 4 |
|
Vericiguat | SGC | Heart Failure | 2021-01, US | 2031-05 |
|
| 5 |
|
Finerenone | MR | Diabetic Nephropathy | 2021-07, US | 2029-04 |
|
| 6 |
|
Daprodustat | HIF-PHs | CDK Induced Anemia | 2020-06, JP | 2028-12 |
|
| 7 |
|
Darolutamide | AR | Castration-Resistant Prostatic Cancer | 2019-07, US | 2030-10 |
|
| 8 |
|
Larotrectinib | NTRK | Tumors/Solid Tumors | 2018-11, US | 2029-10 |
|
| 9 |
|
Acalabrutinib | BTK | Mantle Cell Lymphoma | 2017-10, US | 2032-07 |
|
| 10 |
|
Abemaciclib | CDK4/6 | Breast Cancer | 2017-09, US | 2029-12 |
|
| 11 |
|
Venetoclax | Bcl-2 | Chronic Lymphocytic Leukemia | 2016-04, US | 2031-06 |
|
| 12 |
|
Osimertinib | EGFR | Non-Small Cell Lung Cancer | 2015-11, US | 2032-07 |
|
